![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2023
Isfort, Susanne 
ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
2020
Saussele, Susanne; Haverkamp, Wilhelm; Lang, Fabian; Koschmieder, Steffen; Kiani, Alexander; Jentsch-Ullrich, Kathleen; Stegelmann, Frank; Pfeifer, Heike; La Rosee, Paul; Goekbuget, Nicola; Rieger, Christina; Waller, Cornelius F.; Franke, Georg-Nikolaus; le Coutre, Philipp; Kirchmair, Rudolf und Junghanss, Christian
(2020):
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
In: Acta Haematologica, Bd. 143, Nr. 3: S. 217-231
2018
Saussele, Susanne; Hehlmann, Rüdiger; Fabarius, Alice; Jeromin, Sabine; Proetel, Ulrike; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Einsele, Hermann; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Oppliger Leibundgut, Elisabeth; Heim, Dominik; Krause, Stefan W.; Hofmann, Wolf-Karsten; Hasford, Joerg; Pfirrmann, Markus; Müller, Martin C.; Hochhaus, Andreas und Lauseker, Michael
(2018):
Defining therapy goals for major molecular remission in chronic myeloid leukemia: Results of the randomized CML Study IV.
In: Leukemia, Bd. 32, Nr. 5: S. 1222-1228
[PDF, 599kB]
2015
Tapper, William; Jones, Amy V.; Kralovics, Robert; Harutyunyan, Ashot S.; Zoi, Katerina; Leung, William; Godfrey, Anna L.; Guglielmelli, Paola; Callaway, Alison; Ward, Daniel; Aranaz, Paula; White, Helen E.; Waghorn, Katherine; Lin, Feng; Chase, Andrew; Baxter, E. Joanna; Maclean, Cathy; Nangalia, Jyoti; Chen, Edwin; Evans, Paul; Short, Michael; Jack, Andrew; Wallis, Louise; Oscier, David; Duncombe, Andrew S.; Schuh, Anna; Mead, Adam J.; Griffiths, Michael; Ewing, Joanne; Gale, Rosemary E.; Schnittger, Susanne; Haferlach, Torsten; Stegelmann, Frank; Döhner, Konstanze; Grallert, Harald; Strauch, Konstantin; Tanaka, Toshiko; Bandinelli, Stefania; Giannopoulos, Andreas; Pieri, Lisa; Mannarelli, Carmela; Gisslinger, Heinz; Barosi, Giovanni; Cazzola, Mario; Reiter, Andreas; Harrison, Claire; Campbell, Peter; Green, Anthony R.; Vannucchi, Alessandro und Cross, Nicholas C. P.
(2015):
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
In: Nature Communications, Bd. 6, 6691
[PDF, 873kB]
2014
Hanfstein, Benjamin; Lauseker, Michael; Hehlmann, Rüdiger; Saussele, Susanne; Erben, Philipp; Dietz, Christian; Fabarius, Alice; Proetel, Ulrike; Schnittger, Susanne; Haferlach, Claudia; Krause, Stefan W.; Schubert, Joerg; Einsele, Hermann; Hänel, Mathias; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Jörg; Hofmann, Wolf-Karsten; Hochhaus, Andreas und Müller, Martin C.
(2014):
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
In: Haematologica, Bd. 99, Nr. 9: S. 1441-1447
[PDF, 784kB]